<DOC>
	<DOC>NCT01343901</DOC>
	<brief_summary>This observational study will evaluate the efficacy and safety of Avastin (bevacizumab) as first-line treatment in patients with colorectal cancer and potentially resectable liver metastases. Data will be collected from each from each patient for 36 months.</brief_summary>
	<brief_title>An Observational Study on Avastin (Bevacizumab) as First-Line Treatment in Colorectal Cancer Patients With Potentially Resectable Liver Metastases (PICASSO)</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>Adult patients, &gt;/= 18 years of age Colorectal cancer with exclusively hepatic or hepatic and pulmonary metastases Firstline treatment with Avastin for potentially resectable metastatic disease Outright resectable disease Clearly inoperable disease Participation in a clinical trial evaluating a cytotoxic anticancer treatment and/or an innovative therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>